The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Health Catalyst Inc (NASDAQ: HCAT) closed at $6.65 down -1.92% from its previous closing price of $6.78. In other words, the price has decreased by -$1.92 from its previous closing price. On the day, 0.96 million shares were traded. HCAT stock price reached its highest trading level at $6.68 during the session, while it also had its lowest trading level at $6.37.
Ratios:
For a deeper understanding of Health Catalyst Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.39 and its Current Ratio is at 4.39. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.67.
On January 03, 2024, Evercore ISI Upgraded its rating to Outperform which previously was In-line but kept the price unchanged to $11.
On January 03, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $14.Barclays initiated its Overweight rating on January 03, 2024, with a $14 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 15 ’24 when Llewelyn Linda sold 2,005 shares for $6.11 per share. The transaction valued at 12,251 led to the insider holds 126,226 shares of the business.
Llewelyn Linda sold 2,005 shares of HCAT for $15,648 on Mar 15 ’24. The Chief People Officer now owns 128,231 shares after completing the transaction at $7.80 per share. On Feb 27 ’24, another insider, Burton Daniel D., who serves as the Chief Executive Officer of the company, bought 26,200 shares for $7.81 each. As a result, the insider paid 204,525 and bolstered with 1,172,623 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HCAT now has a Market Capitalization of 392572768 and an Enterprise Value of 328397184. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.33 while its Price-to-Book (P/B) ratio in mrq is 1.06. Its current Enterprise Value per Revenue stands at 1.11 whereas that against EBITDA is -6.169.
Stock Price History:
The Beta on a monthly basis for HCAT is 1.33, which has changed by -0.31237322 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, HCAT has reached a high of $14.37, while it has fallen to a 52-week low of $5.45. The 50-Day Moving Average of the stock is -6.31%, while the 200-Day Moving Average is calculated to be -26.95%.
Shares Statistics:
For the past three months, HCAT has traded an average of 649.06K shares per day and 712160 over the past ten days. A total of 58.30M shares are outstanding, with a floating share count of 56.16M. Insiders hold about 4.86% of the company’s shares, while institutions hold 90.02% stake in the company. Shares short for HCAT as of 1713139200 were 1758337 with a Short Ratio of 2.71, compared to 1710460800 on 1822781. Therefore, it implies a Short% of Shares Outstanding of 1758337 and a Short% of Float of 3.04.
Earnings Estimates
Current recommendations for the stock of the company come from 14.0 analysts. On average, analysts expect EPS of $0.03 for the current quarter, with a high estimate of $0.06 and a low estimate of -$0.06, while EPS last year was $0.05. The consensus estimate for the next quarter is $0.08, with high estimates of $0.12 and low estimates of $0.01.
Analysts are recommending an EPS of between $0.45 and -$0.01 for the fiscal current year, implying an average EPS of $0.32. EPS for the following year is $0.5, with 15.0 analysts recommending between $0.65 and $0.35.
Revenue Estimates
A total of 16 analysts believe the company’s revenue will be $74.8M this quarter.It ranges from a high estimate of $75.5M to a low estimate of $74.05M. As of the current estimate, Health Catalyst Inc’s year-ago sales were $71.24MFor the next quarter, 16 analysts are estimating revenue of $75.55M. There is a high estimate of $76.97M for the next quarter, whereas the lowest estimate is $74.59M.
A total of 17 analysts have provided revenue estimates for HCAT’s current fiscal year. The highest revenue estimate was $311.4M, while the lowest revenue estimate was $306.03M, resulting in an average revenue estimate of $308.68M. In the same quarter a year ago, actual revenue was $295.94MBased on 17 analysts’ estimates, the company’s revenue will be $344.82M in the next fiscal year. The high estimate is $351.98M and the low estimate is $337.8M.
